Printer-friendly versionPrinter-friendly version

2015 - Reference list of hepatitis publications of the VHPB board members

Strategies to manage hepatitis C virus (HCV) infection disease burden - volume 2.
Gane E, Kershenobich D, Seguin-Devaux C, ..., Chulanov V, et al.
J Viral Hepat. 2015 Jan;22 Suppl 1:46-73. doi: 10.1111/jvh.12352.
The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2.
Hatzakis A, Chulanov V, et al.
J Viral Hepat. 2015 Jan;22 Suppl 1:26-45. doi: 10.1111/jvh.12351.
Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 2.
Saraswat V, Norris S, de Knegt RJ, ..., Chulanov V, et al.
J Viral Hepat. 2015 Jan;22 Suppl 1:6-25. doi: 10.1111/jvh.12350.
Hepatitis C virus treatment in the real world: optimising treatment and access to therapies.
Zoulim F, Liang TJ, Gerbes AL, Aghemo A, Deuffic-Burban S, Dusheiko G, Fried MW, Pol S, Rockstroh JK, Terrault NA, Wiktor S.
Gut. 2015 Nov;64(11):1824-33. doi: 10.1136/gutjnl-2015-310421. Review.
Global policy and access to new hepatitis C therapies for people who inject drugs.
Doyle JS, Aspinall EJ, Hutchinson SJ, Quinn B, Gore C, Wiktor SZ, Hellard ME.
Int J Drug Policy. 2015 Nov;26(11):1064-71. doi: 10.1016/j.drugpo.2015.05.008. Epub 2015 Jun 2.
Ten priorities for expanding access to HCV treatment for people who inject drugs in low- and middle-income countries.
Ford N, Wiktor S, Kaplan K, Andrieux-Meyer I, Hill A, Radhakrishnan P, Londeix P, Forette C, Momenghalibaf A, Verster A, Swan T.
Int J Drug Policy. 2015 Nov;26(11):1088-93. doi: 10.1016/j.drugpo.2015.05.004. Epub 2015 May 18.
Deciding who should be treated for hepatitis C infection in a rapidly changing therapeutic landscape.
Wiktor SZ.
Hepatology. 2015 Jul;62(1):13-5. doi: 10.1002/hep.27810. Epub 2015 May 29. No abstract available.
Where next for hepatitis B and C surveillance?
Wiktor SZ.
J Viral Hepat. 2015 Jul;22(7):571-3. doi: 10.1111/jvh.12400. Epub 2015 Mar 6.
Substantial decline in hepatitis B virus infections following vaccine introduction in Tajikistan.
Khetsuriani N, Tishkova F, Jabirov S, Wannemuehler K, Kamili S, Pirova Z, Mosina L, Gavrilin E, Ursu P, Drobeniuc J.
Vaccine. 2015 Jul 31;33(32):4019-24. doi: 10.1016/j.vaccine.2015.05.092. Epub 2015 Jun 10.
Strengthening national decision-making on immunization by building capacity for economic evaluation: Implementing ProVac in Europe.
Blau J, Hoestlandt C, D Clark A, Baxter L, Felix Garcia AG, Mounaud B, Mosina L.
Vaccine. 2015 May 7;33 Suppl 1:A34-9. doi: 10.1016/j.vaccine.2014.12.073.
Historical epidemiology of hepatitis C virus (HCV) in select countries - volume 3.
Liakina V, Hamid S, Tanaka J, Olafsson S, ..., Matičič M, ...
J Viral Hepat. 2015 Dec;22 Suppl 4:4-20. doi: 10.1111/jvh.12475.
The present and future disease burden of hepatitis C virus infections with today's treatment paradigm - volume 3.
Sibley A, Han KH, Abourached A,..., Matičič M, ...
J Viral Hepat. 2015 Dec;22 Suppl 4:21-41. doi: 10.1111/jvh.12476.
Strategies to manage hepatitis C virus infection disease burden - volume 3.
Alfaleh FZ, Nugrahini N, Matičič M, et al.
J Viral Hepat. 2015 Dec;22 Suppl 4:42-65. doi: 10.1111/jvh.12474.
Changes in the epidemiology of hepatitis A outbreaks 13 years after the introduction of a mass vaccination program.
Martínez A, Broner S, Sala MR, Manzanares-Laya S, Godoy P, Planas C, Minguell S, Torner N, Jané M, Domínguez A.
Hum Vaccin Immunother. 2015;11(1):192-7. doi: 10.4161/hv.35861.
Acute hepatitis E virus in pregnant women in Israel and in other industrialized countries.
Lachish T, Erez O, Daudi N, Shouval D, Schwartz E.
J Clin Virol. 2015 Oct 19;73:20-24.
Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort).
Pierre N, Lescat M, Layese R, ..., Roudot-Thoraval F, for the ANRS CO12 CirVir and Microcir Groups.
gutjnl-2015-310275.
Simple, Effective, but Out of Reach? Public Health Implications of HCV Drugs.
Ward JW,Mermin JH.
N Engl J Med. 2015 Dec 31;373(27):2678-80. doi: 10.1056/NEJMe1513245. Epub 2015 Nov 17.
Update: Shortened Interval for Postvaccination Serologic Testing of Infants Born to Hepatitis B-Infected Mothers.
Schillie S, Murphy TV, Fenlon N, Ko S, Ward JW.
MMWR Morb Mortal Wkly Rep. 2015 Oct 9;64(39):1118-20. doi: 10.15585/mmwr.mm6439a6.
Launch of a Nationwide Hepatitis C Elimination Program--Georgia, April 2015.
Mitruka K, Tsertsvadze T, Butsashvili M, Gamkrelidze A, Sabelashvili P, Adamia E, Chokheli M, Drobeniuc J, Hagan L, Harris AM, Jiqia T, Kasradze A, Ko S, Qerashvili V, Sharvadze L, Tskhomelidze I, Kvaratskhelia V, Morgan J, Ward JW, Averhoff F.
MMWR Morb Mortal Wkly Rep. 2015 Jul 24;64(28):753-7. Erratum in: MMWR Morb Mortal Wkly Rep. 2015 Jul 31;64(29):806.
Cost-effectiveness of strategies for testing current hepatitis C virus infection.
Chapko MK, Dufour DR, Hatia RI, Drobeniuc J, Ward JW, Teo CG.
Hepatology. 2015 Nov;62(5):1396-404. doi: 10.1002/hep.27966. Epub 2015 Aug 25.
Increases in hepatitis C virus infection related to injection drug use among persons aged ≤30 years - Kentucky, Tennessee, Virginia, and West Virginia, 2006-2012.
Zibbell JE, Iqbal K, Patel RC, Suryaprasad A, Sanders KJ, Moore-Moravian L, Serrecchia J, Blankenship S, Ward JW, Holtzman D; Centers for Disease Control and Prevention (CDC).
MMWR Morb Mortal Wkly Rep. 2015 May 8;64(17):453-8.
The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus.
Rein DB, Wittenborn JS, Smith BD, Liffmann DK, Ward JW.
Clin Infect Dis. 2015 Jul 15;61(2):157-68. doi: 10.1093/cid/civ220.
Making hepatitis E a vaccine-preventable disease.
Teshale E, Ward JW.
N Engl J Med. 2015 Mar 5;372(10):899-901. doi: 10.1056/NEJMp1415240.
Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease.
Leidner AJ, Chesson HW, Xu F, Ward JW, Spradling PR, Holmberg SD.
Hepatology. 2015 Jun;61(6):1860-9. doi: 10.1002/hep.27736.
Estimates on HCV disease burden worldwide - filling the gaps.
Wedemeyer H, Dore GJ, Ward JW.
J Viral Hepat. 2015 Jan;22 Suppl 1:1-5. doi: 10.1111/jvh.12371.
Enhanced surveillance of hepatitis C in the EU, 2006-2012.
Duffell EF, van de Laar MJ, Amato-Gauci AJ.
J Viral Hepat. 2015 Jul;22(7):590-5.
Enhanced surveillance of hepatitis B in the EU, 2006-2012.
Duffell EF, van de Laar MJ, Amato-Gauci AJ.
J Viral Hepat. 2015 Jul;22(7):581-9.
Lessons learnt over two decades of vaccination against hepatitis B in Italy.
Romano’ L, Galli C, Zanetti ARA..
Journal of Preventive Medicine and Hygiene, 2015; 56:E12-14.
Outbreaks of hepatitis A associated with immigrants travelling to visit friends and relatives.
Godoy P, Broner S, Manzanares-Laya S, Martínez A, Parrón I, Planas C, Sala-Farré MR, Minguell S, de Olalla PG, Jané M, Dominguez A; Working Group for the Study of Hepatitis A in Catalonia.
J Infect. 2015 Sep 21. pii: S0163-4453(15)00284-4. doi: 10.1016/j.jinf.2015.09.006.
Survey of surveillance systems and select prevention activities for hepatitis B and C, European Union/European Economic Area, 2009.
Duffell EF, van de Laar MJ.
Euro surveillance : bulletin Europeen sur les maladies transmissibles Apr 2;20(13):17-24
Evidence of continued injecting drug use after attaining sustained treatment-induced clearance of the hepatitis C virus: Implications for reinfection.
Valerio H, Goldberg DJ, Lewsey J, Weir A, Allen S, Aspinall EJ, Barclay ST, Bramley P, Dillon JF, Fox R, Fraser A, Hayes PC, Innes H, Kennedy N, Mills PR, Stanley AJ, Hutchinson SJ.
Drug Alcohol Depend. 2015 Sep 1;154:125-31. doi: 10.1016/j.drugalcdep.2015.06.032.
Expansion of HCV treatment access to people who have injected drugs through effective translation of research into public health policy: Scotland's experience.
Hutchinson SJ, Dillon JF, Fox R, McDonald SA, Innes HA, Weir A, McLeod A, Aspinall EJ, Palmateer NE, Taylor A, Munro A, Valerio H, Brown G, Goldberg DJ.
Int J Drug Policy. 2015 Nov;26(11):1041-9. doi: 10.1016/j.drugpo.2015.05.019.
Estimating the number of people with hepatitis C virus who have ever injected drugs and have yet to be diagnosed: an evidence synthesis approach for Scotland.
Prevost TC, Presanis AM, Taylor A, Goldberg DJ, Hutchinson SJ, De Angelis D.
Addiction. 2015 Aug;110(8):1287-300. doi: 10.1111/add.12948. 
Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes.
Innes HA, McDonald SA, Dillon JF, Allen S, Hayes PC, Goldberg D, Mills PR, Barclay ST, Wilks D, Valerio H, Fox R, Bhattacharyya D, Kennedy N, Morris J, Fraser A, Stanley AJ, Bramley P, Hutchinson SJ.
Hepatology. 2015 Aug;62(2):355-64. doi: 10.1002/hep.27766
Targeted hepatitis C antibody testing interventions: a systematic review and meta-analysis.
Aspinall EJ, Doyle JS, Corson S, Hellard ME, Hunt D, Goldberg D, Nguyen T, Falck-Ytter Y, Morgan RL, Smith B, Stoove M, Wiktor SZ, Hutchinson S.
Eur J Epidemiol. 2015 Feb;30(2):115-29. doi: 10.1007/s10654-014-9958-4.
Strategies for the treatment of Hepatitis C in an era of interferon-free therapies: what public health outcomes do we value most?
Innes H, Goldberg D, Dillon J, Hutchinson SJ.
Gut. 2015 Nov;64(11):1800-9. doi: 10.1136/gutjnl-2014-308166.
HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact.
Martin NK, Foster GR, Vilar J, Ryder S, Cramp ME, Gordon F, Dillon JF, Craine N, Busse H, Clements A, Hutchinson SJ, Ustianowski A, Ramsay M, Goldberg DJ, Irving W, Hope V, De Angelis D, Lyons M, Vickerman P, Hickman M.
J Viral Hepat. 2015 Apr;22(4):399-408. doi: 10.1111/jvh.12338
Trends in mortality after diagnosis of hepatitis C virus infection: an international comparison and implications for monitoring the population impact of treatment.
Aspinall EJ, Hutchinson SJ, Janjua NZ, Grebely J, Yu A, Alavi M, Amin J, Goldberg DJ, Innes H, Law M, Walter SR, Krajden M, Dore GJ.
J Hepatol. 2015 Feb;62(2):269-77. doi: 10.1016/j.jhep.2014.09.001.
What is the impact of a country-wide scale-up in antiviral therapy on the characteristics and sustained viral response rates of patients treated for hepatitis C?
McDonald SA, Innes HA, Hayes PC, Dillon JF, Mills PR, Goldberg DJ, Barclay S, Allen S, Fox R, Fraser A, Kennedy N, Bhattacharyya D, Hutchinson SJ.
J Hepatol. 2015 Feb;62(2):262-8. doi: 10.1016/j.jhep.2014.08.046.
HCV treatment as prevention in prison: key issues.
Martin NK, Vickerman P, Goldberg D, Hickman M.
Hepatology. 2015 Jan;61(1):402-3. doi: 10.1002/hep.27194
Prevalence of HBV and HCV among outpatients in the Plovdiv region of Bulgaria, 2010-2011.
Kevorkyan A1, Teoharov P, Lernout T, Petrova N, Raycheva R, Ivanov I, van Damme P, Kojouharova M.
J Med Virol. 2015 Mar;87(3):401-6. doi: 10.1002/jmv.24065.
Diagnostic performance of five assays for anti-HEV IgG and IgM in a large cohort study.
Norder H, Karlsson M, Mellgren Å, Konar J, Sandberg E, Lasson A, Castedal M, Magnius L, Lagging M.
J Clin Microbiol. 2015 Dec 9. pii: JCM.02343-15.
Chronic hepatitis E infection with an emerging virus strain in a heart transplant recipient successfully treated with ribavirin: a case report.
Waldenström J, Castedal M, Konar J, Karason K, Lagging M, Norder H.
J Med Case Rep. 2015 Aug 26;9:180. doi: 10.1186/s13256-015-0655-z.
Incidence of Hepatitis E Antibodies in Swedish Lung Transplant Recipients.
Magnusson J, Norder H, Riise GC, Andersson LM, Brittain-Long R, Westin J.
Transplant Proc. 2015 Jul-Aug;47(6):1972-6. doi: 10.1016/j.transproceed.2015.04.092.
High prevalence of hepatitis e virus in Swedish moose--a phylogenetic characterization and comparison of the virus from different regions.
Lin J, Karlsson M, Olofson AS, Belák S, Malmsten J, Dalin AM, Widén F, Norder H.
PLoS One. 2015 Apr 23;10(4):e0122102. doi: 10.1371/journal.pone.0122102.
High incidence of the hepatitis C virus recombinant 2k/1b in Georgia: Recommendations for testing and treatment.
Karchava M, Waldenström J, Parker M, Hallack R, Sharvadze L, Gatserelia L, Chkhartishvili N, Dvali N, Dzigua L, Dolmazashvili E, Norder H, Tsertsvadze T.
Hepatol Res. 2015 Feb 16. doi: 10.1111/hepr.12505.
Three decades of hepatitis B control with vaccination.
Meireles LC, Marinho RT, Van Damme P.
World J Hepatol. 2015 Aug 28;7(18):2127-32. doi: 10.4254/wjh.v7.i18.2127.
Considerations on the current universal vaccination policy against hepatitis A in Greece after recent outbreaks.
Mellou K, Sideroglou T, Papaevangelou V, Katsiaflaka A, Bitsolas N, Verykouki E, Triantafillou E, Baka A, Georgakopoulou T, Hadjichristodoulou C.
PLoS One. 2015 Jan 15;10(1):e0116939. doi: 10.1371/journal.pone.0116939
Hepatitis B vaccine alone or with hepatitis B immunoglobulin in neonates of HBsAg+/HBeAg- mothers: a systematic review and meta-analysis.
Machaira M, Papaevangelou V, Vouloumanou EK, Tansarli GS, Falagas ME.
J Antimicrob Chemother. 2015 Feb;70(2):396-404. doi: 10.1093/jac/dku404
Dried Blood Spots: A Tool to Ensure Broad Access to Hepatitis C Screening, Diagnosis, and Treatment Monitoring.
Soulier A, Poiteau L, Rosa I, Hézode C, Roudot-Thoraval F, Pawlotsky JM, Chevaliez S.
J Infect Dis. 2015 Sep 2. pii: jiv423
Cure of hepatitis C.
Roudot-Thoraval F.
Acta Med Port. 2015 Jan-Feb;28(1):10-1
Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S vaccine.
Shouval D, Roggendorf H, Roggendorf M.
Med Microbiol Immunol. 2015 Feb;204(1):57-68. doi: 10.1007/s00430-014-0374-x.
Long-term antibody persistence after vaccination with a 2-dose Havrix™ (inactivated hepatitis A vaccine): 20 years of observed data, and long-term model-based predictions.
Theeten H, Van Herck K, Van Der Meeren O, Crasta P, Van Damme P, Hens N.
Vaccine. 2015 Oct 13;33(42):5723-7. doi: 10.1016/j.vaccine
Long-term antibody persistence in children after vaccination with the pediatric formulation of an aluminum-free virosomal hepatitis A vaccine.
Van Herck K, Hens A, De Coster I, Vertruyen A, Tolboom J, Sarnecki M, Van Damme P.
Pediatr Infect Dis J. 2015 Apr;34(4):e85-91. doi: 10.1097/INF.0000000000000616.
Update: Shortened Interval for Postvaccination Serologic Testing of Infants Born to Hepatitis B-Infected Mothers.
Schillie S, Murphy TV, Fenlon N, Ko S, Ward JW.
MMWR Morb Mortal Wkly Rep. 2015 Oct 9;64(39):1118-20. doi: 10.15585/mmwr.mm6439a6.
Launch of a Nationwide Hepatitis C Elimination Program--Georgia, April 2015.
Mitruka K, Tsertsvadze T, Butsashvili M, Gamkrelidze A, Sabelashvili P, Adamia E, Chokheli M, Drobeniuc J, Hagan L, Harris AM, Jiqia T, Kasradze A, Ko S, Qerashvili V, Sharvadze L, Tskhomelidze I, Kvaratskhelia V, Morgan J, Ward JW, Averhoff F.
MMWR Morb Mortal Wkly Rep. 2015 Jul 24;64(28):753-7. Erratum in: MMWR Morb Mortal Wkly Rep. 2015 Jul 31;64(29):806.
Clinical, epidemiological and virological features of acute hepatitis B in Italy.
Zuccaro O, Romanò L, Mele A, Mariano A, Clementi M, Tosti ME, Taliani G, Galli C, Zanetti AR, Spada E; Study Group.
Infection. 2015 Aug;43(4):431-41. doi: 10.1007/s15010-015-0747-0
Hepatitis B vaccination.
Romanò L, Paladini S, Galli C, Raimondo G, Pollicino T, Zanetti AR.
Hum Vaccin Immunother. 2015;11(1):53-7. doi: 10.4161/hv.34306.
The Disease Burden of Hepatitis C in Belgium : An update of a realistic disease control strategy.
Stärkel P, Vandijck D, Laleman W, Van Damme P, Moreno C, Blach S, Razavi H, Van Vlierberghe H.
Acta Gastroenterol Belg. 2015 Jun;78(2):228-32.
Coverage of the expanded program on immunization in Vietnam: Results from 2 cluster surveys and routine reports.
Nguyen TD, Dang AD, Van Damme P, Nguyen CV, Duong HT, Goossens H, Theeten H, Leuridan E.
Hum Vaccin Immunother. 2015;11(6):1526-33.
Usefulness of a fourth generation ELISA assay for the reliable identification of HCV infection in HIV-positive adults from Gabon (Central Africa).
Rouet F, Deleplancque L, Mboumba BB, Sica J, Mouinga-Ondémé A, Liégeois F, Goudeau A, Dubois F, Gaudy-Graffin C.
PLoS One. 2015 Jan 24;10(1):e0116975. doi: 10.1371/journal.pone.0116975
Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland.
Müllhaupt B, Bruggmann P, Bihl F, Blach S, Lavanchy D, Razavi H, Semela D, Negro F.
PLoS One. 2015 Jun 24;10(6):e0125214. doi: 10.1371/journal.pone.0125214.
Birth cohort distribution and screening for viraemic hepatitis C virus infections in Switzerland.
Bruggmann P, Negro F, Bihl F, Blach S, Lavanchy D, Müllhaupt B, Razavi H, Semela D.
Swiss Med Wkly. 2015 Dec 4;145:w14221. doi: 10.4414/smw.2015.14221.
Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in Swiss patients with chronic hepatitis C.
Pfeil AM, Reich O, Guerra IM, Cure S, Negro F, Müllhaupt B, Lavanchy D, Schwenkglenks M.
PLoS One. 2015 May 14;10(5):e0126984. doi: 10.1371/journal.pone.0126984. 

Hepatotoxicity of herbal and dietary supplements: an update.

Stickel F, Shouval D.

Arch Toxicol. 2015 Jun;89(6):851-65. doi: 10.1007/s00204-015-1471-3. Review.